A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Mise à jour : Il y a 4 ans
Référence : NCT02441946

Femme Homme

Extrait

The purpose of this study is to evaluate the biological effects of abemaciclib in combination with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone in the tumors of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.


Critère d'inclusion

  • Breast Cancer ,Hormone Receptor Positive Tumor ,Early-Stage Breast Carcinoma


Liens